Gastroenteropancreatic Neuroendocrine Neoplasms: Epidemiology, Genetics, and Treatment

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Oct 16

PMID 39411312

Authors

Baizhou Tan

Beiyu Zhang

Hongping Chen

Affiliations

Soon will be listed here.

Abstract

The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) is increasing at a rapid pace and is becoming an increasingly important consideration in clinical care. Epidemiological data from multiple countries indicate that the incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) exhibits regional, site-specific, and gender-based variations. While the genetics and pathogenesis of some GEP NEN, particularly pancreatic NENs, have been investigated, there are still many mechanisms that require further investigation. The management of GEP NEN is diverse, but surgery remains the primary option for most cases. Peptide receptor radionuclide therapy (PRRT) is an effective treatment, and several clinical trials are exploring the potential of immunotherapy and targeted therapy, as well as combination therapy.

Citing Articles

Autoimmune Pancreatitis Mimicking a Pancreatic Neuroendocrine Tumor: A Case Report with a Literature Review.

Franchina M, DellOro L, Massironi S Int J Mol Sci. 2025; 26(4).

PMID: 40004001 PMC: 11855540. DOI: 10.3390/ijms26041536.

References

Benitez J, Ma J, DAntonio M, Boyer A, Camargo M, Zanca C . PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2017; 8:15223. PMC: 5437297. DOI: 10.1038/ncomms15223. View

White B, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M . Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study. Lancet Reg Health Eur. 2022; 23:100510. PMC: 9513765. DOI: 10.1016/j.lanepe.2022.100510. View

Bellefkih F, Benchakroun N, Lalya I, Amaoui B, El Kacemi H, Acharki A . Radiotherapy in the management of rare gastrointestinal cancers: A systematic review. Cancer Radiother. 2023; 27(6-7):622-637. DOI: 10.1016/j.canrad.2023.06.010. View

Samsom K, Levy S, van Veenendaal L, Roepman P, Kodach L, Steeghs N . Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours. Histopathology. 2020; 78(4):556-566. DOI: 10.1111/his.14252. View

Choueiri T, Bauer T, Papadopoulos K, Plimack E, Merchan J, Mcdermott D . Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021; 27(5):802-805. PMC: 9128828. DOI: 10.1038/s41591-021-01324-7. View

Li S, Essaghir A, Martijn C, Lloyd R, Demoulin J, Oberg K . Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol. 2013; 26(5):685-96. PMC: 3647117. DOI: 10.1038/modpathol.2012.216. View

Miller H, Frampton A, Malczewska A, Ottaviani S, Stronach E, Flora R . MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocr Relat Cancer. 2016; 23(9):711-26. DOI: 10.1530/ERC-16-0044. View

Sorbye H, Kong G, Grozinsky-Glasberg S . PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2019; 27(3):R67-R77. DOI: 10.1530/ERC-19-0400. View

Pavel M, Valle J, Eriksson B, Rinke A, Caplin M, Chen J . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017; 105(3):266-280. DOI: 10.1159/000471880. View

10.

Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P . Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017; 543(7643):65-71. DOI: 10.1038/nature21063. View

11.

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

12.

Hackeng W, Brosens L, Kim J, OSullivan R, Sung Y, Liu T . Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2021; 71(5):961-973. PMC: 8511349. DOI: 10.1136/gutjnl-2020-322595. View

13.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

14.

Arnold R, Rinke A, Klose K, Muller H, Wied M, Zamzow K . Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005; 3(8):761-71. DOI: 10.1016/s1542-3565(05)00481-7. View

15.

Drane P, Ouararhni K, Depaux A, Shuaib M, Hamiche A . The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010; 24(12):1253-65. PMC: 2885661. DOI: 10.1101/gad.566910. View

16.

Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, Della Peruta M . Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2009; 28(2):245-55. PMC: 4288616. DOI: 10.1200/JCO.2008.21.5988. View

17.

Chan D, Singh S . Current Chemotherapy Use in Neuroendocrine Tumors. Endocrinol Metab Clin North Am. 2018; 47(3):603-614. DOI: 10.1016/j.ecl.2018.04.006. View

18.

Garcia-Alvarez A, Hernando Cubero J, Capdevila J . Drug Development in Neuroendocrine Tumors: What Is on the Horizon?. Curr Treat Options Oncol. 2021; 22(5):43. DOI: 10.1007/s11864-021-00834-3. View

19.

Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J . Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Endocr Relat Cancer. 2017; 24(2):L21-L25. DOI: 10.1530/ERC-16-0419. View

20.

Vezzosi D, Cardot-Bauters C, Bouscaren N, Lebras M, Bertholon-Gregoire M, Niccoli P . Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study. Eur J Endocrinol. 2014; 172(3):309-19. DOI: 10.1530/EJE-14-0878. View